Cost Of Sovaldi And Other Specialty Drugs Worries States, Pharmaceutical Executives
"The prospect that hepatitis-C drug sales could soar to $20 billion annually by the end of the decade is spurring attempts by drug companies to assert the patent rights they'll need to grab a piece of the pie"Yeah, it's funny how when they finally find an effective treatment, there's a huge market for it..
"CVS officials write in a commentary published Sunday. Gilead’s Sovaldi “is not really a per-unit cost outlier, but is a ‘total cost’ outlier because of its high cost combined with a very large population eligible for treatment — and a beacon for costs of specialty medications generally,”
This is going to get ugly, the insurance companies are figuring out the Pharmas have rigged things to blow up the whole game if they don't win...
